Results 11 to 20 of about 567,668 (313)

Macroprolactinoma with secondary resistance to dopamine agonists: a case report and review of the literature  [PDF]

Journal of Medical Case Reports, 2023
Background Resistance to dopamine agonists is not uncommonly seen in prolactinomas. However, development of resistance to dopamine agonists after an initial period of robust treatment response is rare, and only 39 cases have been reported in the past ...
Eng-Loon Tng, Ada Ee Der Teo, Aye Thida Aung   +2 more
doaj   +2 more sources

Impulse control disorders and use of dopamine agonists in early onset Parkinson’s disease [PDF]

Frontiers in Neurology
IntroductionImpulse control disorders (ICDs) are defined as excessive and repetitive behaviors that may affect Parkinson’s disease (PD) patients exposed to dopamine agonists. Current data on ICDs in patients with early-onset Parkinson’s disease (EOPD) is
Pierpaolo Turcano, Jessie Jacobson, Khaled Ghoniem, Aidan Mullan, Emanuele Camerucci, Cole Stang, Capucine Piat, James H. Bower, Rodolfo Savica   +8 more
doaj   +2 more sources

Impaired β-arrestin recruitment and reduced desensitization by non-catechol agonists of the D1 dopamine receptor

Nature Communications, 2018
Dopamine receptor agonists are used for the treatment of various psychiatric diseases. Here, the authors screen approximately three million compounds and identify a novel class of D1R agonists that do not have a catechol scaffold and possess promising ...
David L. Gray, John A. Allen, Scot Mente, Rebecca E. O’Connor, George J. DeMarco, Ivan Efremov, Patrick Tierney, Dmitri Volfson, Jennifer Davoren, Edward Guilmette, Michelle Salafia, Rouba Kozak, Michael D. Ehlers   +12 more
doaj   +2 more sources

Impulse control disorders and dopamine agonists [PDF]

European Psychiatry, 2021
Introduction Impulse control disorders (ICDs) are an adverse effect of dopamine agonists (DAAs) that affects the quality of life and can lead to legal, criminal and familiar problems.
D. Martins, R. Faria, M. Pinho, S. Rodrigues   +3 more
doaj   +2 more sources

Dopamine Agonists and Pathologic Behaviors

Parkinson's Disease, 2012
The dopamine agonists ropinirole and pramipexole exhibit highly specific affinity for the cerebral dopamine D3 receptor. Use of these medications in Parkinson’s disease has been complicated by the emergence of pathologic behavioral patterns such as ...
Brendan J. Kelley, Andrew P. Duker, Peter Chiu   +2 more
doaj   +2 more sources

Dopamine dysregulation syndrome after prescription of dopamine agonists: a case report [PDF]

European Psychiatry, 2022
Introduction We present the case of a 65-year-old woman with multiple and chronic psychosomatic symptoms. Due to motor impairments she was diagnosed in 2009 with Parkinson’s Disease (PD) by the neurology department and empirical treatment with levodopa ...
M.L. Costa, A. Cerame
doaj   +2 more sources

7778 Factors Predicting Recovery of Hypogonadism in Men with Prolactinoma Treated with Dopamine Agonists [PDF]

J Endocr Soc
Stefan Matei Constantinescu, Orsalia Alexopoulou, Dominique Maiter   +2 more
europepmc   +3 more sources

Incident mental health episodes after initiation of gabapentinoids vs. dopamine agonists for early-onset idiopathic restless legs syndrome. [PDF]

Psychiatry Res, 2023
Costales B, Vouri SM, Brown JD, Setlow B, Goodin AJ.   +4 more
europepmc   +3 more sources

From Selye’s and Szabo’s Cysteamine-Duodenal Ulcer in Rats to Dopamine in the Stomach: Therapy Significance and Possibilities

Pharmaceuticals, 2023
We reviewed gastric ulcer healing by dopamine considering several distinctive duodenal key points. Selye and Szabo describe the cysteamine-induced duodenal ulcer in rats as a duodenal stress ulcer in patients.
Predrag Sikiric, Alenka Boban Blagaic, Ivan Krezic, Helena Zizek, Luka Kalogjera, Ivan Maria Smoday, Vlasta Vukovic, Katarina Oroz, Helen Marie Chiddenton, Sara Buric, Marko Antunovic, Slaven Gojkovic, Sanja Strbe, Milena Skocic, Suncana Sikiric, Marija Milavic, Lidija Beketic Oreskovic, Antonio Kokot, Antun Koprivanac, Ivan Dobric, Marko Sever, Mario Staresinic, Lovorka Batelja Vuletic, Anita Skrtic, Sven Seiwerth   +24 more
doaj   +1 more source

Dopamine genetic risk score predicts impulse control behaviors in Parkinson’s disease

Clinical Parkinsonism & Related Disorders, 2021
Introduction: Up to 40% of Parkinson’s disease patients taking dopamine agonist medication develop impulse control behaviors which can have severe negative consequences.
Alison Hall, Samuel R. Weaver, Lindsey J. Compton, Winston D. Byblow, Ned Jenkinson, Hayley J. MacDonald   +5 more
doaj   +1 more source